Status:
ACTIVE_NOT_RECRUITING
Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Allogeneic Hematopoietic Stem Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.
Detailed Description
This is a randomized, open-label, controlled study designed to assess the efficacy of autologous fecal microbiota transplantation (auto-FMT) for prevention of Clostridium difficile infection (CDI) in ...
Eligibility Criteria
Inclusion
- Planned to undergo allo-HSCT
- Age ≥ 18 years
Exclusion
- As determined by the study investigators or consenting professionals, prolonged antibiotic treatment, as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing antianaerobic antibiotics
- Has severe colitis of any etiology or a history of inflammatory bowel disease (IBD).
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2026
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT02269150
Start Date
October 1 2014
End Date
October 1 2026
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065